Jefferies initiated coverage on ImmunityBio with a new price target
$IBRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Jefferies initiated coverage of ImmunityBio with a rating of Buy and set a new price target of $8.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/12/2023 | $10.00 → $4.00 | Overweight → Neutral | Piper Sandler |
| 8/3/2022 | $8.00 | Buy | Jefferies |
FREMONT, Calif., Nov. 21, 2024 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ:IBRX), a vertically integrated biotechnology company, and nCartes, Inc., a transformational cloud software platform provider, announced a collaboration agreement aimed at automating and streamlining the data fulfillment process for clinical trials. The goal of the collaboration is to make this essential process easier, faster, and less expensive for ImmunityBio's trial investigators. The vast majority of clinical trials today gather data manually at clinical research sites. The data is then entered by han
High responder rate associated with a duration of response ranging as long as 54 months in QUILT-3.032 with 100 patients enrolled Updated data intended to be submitted as part of a European Medicines Agency (EMA) Submission in Q4 2024 Complete response data in 100 patients consistent with CR rate of 71% reported for 82 patients published in NEJM ImmunityBio, Inc. ((IBRX), a leading immunotherapy company, today announced compelling new data from its ongoing QUILT 3.032 study. As of November 2024, 100 patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (NMIBC CIS) have been treated with ANKTIVA® (nogapendekin alfa inbak
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Nov. 14, 2024 /PRNewswire/ -- USA News Group News Commentary – As many biotech companies within the oncology space begin to roll out their end-of-quarter results, the American Medical Association is pointing out the alarming trend of rising cancer rates, especially with younger people. According to data released from the National Cancer Institute (NCI), a division of the National Institutes of Health (NIH), a map shared by Newsweek showed that the prevalence of cancer varies significantly from state to state. Thankfully, there are plenty of new breakthroughs in the fight against cancer that the World Eco
SC 13D/A - ImmunityBio, Inc. (0001326110) (Subject)
SC 13D/A - ImmunityBio, Inc. (0001326110) (Subject)
SC 13D/A - ImmunityBio, Inc. (0001326110) (Subject)
Piper Sandler downgraded ImmunityBio from Overweight to Neutral and set a new price target of $4.00 from $10.00 previously
Jefferies initiated coverage of ImmunityBio with a rating of Buy and set a new price target of $8.00
8-K - ImmunityBio, Inc. (0001326110) (Filer)
10-Q - ImmunityBio, Inc. (0001326110) (Filer)
10-Q - ImmunityBio, Inc. (0001326110) (Filer)
4 - ImmunityBio, Inc. (0001326110) (Issuer)
4 - ImmunityBio, Inc. (0001326110) (Issuer)
4 - ImmunityBio, Inc. (0001326110) (Issuer)
These mid-cap stocks were the best performers in the last week. Are they in your portfolio? Bilibili Inc. (NASDAQ:BILI) shares rose 23.32% following last week’s release of ‘San Guo: Mou Ding Tian Xia.’ Also, JP Morgan analyst Daniel Chen upgraded Bilibili from Neutral to Overweight and announced a $21 price forecast. ImmunityBio, Inc. (NASDAQ:IBRX) shares jumped 22.36% on continued strength after the announcement of insurance coverage of ANKTIVA across multiple states with the first commercial doses administered. Sasol Ltd. (NYSE:SSL) shares escalated 20.89% after the company announced that the court ruled in favor of the company and TotalEnergies SE (NYSE:TTE) Marketing. Also, it
ImmunityBio, Inc. ((IBRX) today announced its financial results for the third-quarter ended September 30, 2024. ANKTIVA® received a J-code (HCPCS Level II Code) in October 2024, effective January 1, 2025. ANKTIVA (FDA-approved and commercially available in the U.S. since May 2024) is now widely accessible to patients through commercial and government insurance programs (VA, DoD, Medicare). ImmunityBio has secured coverage for over 200 million medical lives through medical reimbursement policies. ImmunityBio achieved a net product revenue of approximately $6.0 million during the three months ended September 30, 2024, surpassing net product revenue of $1.0 million in the prior quarte
Dr. Sam S. Chang, Professor of Urology at Vanderbilt Cancer Program, to host the program "A Deep Dive with Patrick Soon-Shiong: Next-Generation Immunotherapy for NMBIC" Discussion about the basis for ANKTIVA's Breakthrough Therapy designation and the novel mechanism of how the IL-15 superagonist achieves durable complete responses in BCG unresponsive NMIBC The Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio, Inc. ((IBRX), a next-generation immunotherapy company, will discuss the implications of the recent FDA approval of ANKTIVA® (nogapendekin alfa inbakicept-pmln) for use in combination with bacillus Calmette-Guerin (BCG) for non-muscle invasive bl
QUILT 3.055 trial completed and shows median overall survival almost double that of standard of care chemotherapy in 2nd- and 3rd-line non-small cell lung cancer (NSCLC) patients whose cancer did not respond to checkpoint inhibitors with or without chemotherapy Positive results seen in both PD-L1 negative and PD-L1 positive participants with NSCLC Data reaffirms the mechanism of action of ANKTIVA as an immune cell enhancer that activates natural killer (NK) cells and memory T cells to rescue checkpoint inhibitor (pembrolizumab, nivolumab, atezolizumab) failures across multiple tumor types Meeting scheduled with FDA in June to discuss path to registration filing of ANKTIVA plus che
ImmunityBio, Inc. ((IBRX) announced today that its 2024 Annual Meeting of Stockholders will be held on Tuesday, June 11, 2024 at 9:30 a.m. Pacific Time. The Annual Meeting will be held in a virtual-only format and there will not be a physical location for the Annual Meeting. Stockholders of record at the close of business on April 17, 2024 are entitled to vote at and participate in the Annual Meeting. Richard Adcock, the Company's Chief Executive Officer and President, will provide a business update after the formal business of the Annual Meeting has ended. All interested parties are welcome to attend the Annual Meeting and listen to the Company update. Non-stockholders can attend the vir
- Yun Han named Chief Accounting Officer and Interim Chief Financial Officer - - Initial Funding Expected This Week Under $60 Million Financing Agreement - Faraday Future Intelligent Electric Inc. ("Faraday Future" or the "Company") (NASDAQ:FFIE), a California-based global shared intelligent electric mobility ecosystem company, today announced the appointment of Yun Han as Chief Accounting Officer and Interim Chief Financial Officer, effective October 25, 2022. Ms. Han replaces Becky Roof, who served as interim Chief Financial Officer until October 12, 2022, and is assisting the Company to ensure an orderly transition. This press release features multimedia. View the full release here: htt
Biopharma leaders bring proven market development talents in urology and oncology to bolster company's commercialization plan and long-term growth plans Helen Luu, former CEO of Cell BT, is named ImmunityBio's first Chief Commercial Officer and brings a strong background in product commercialization in the urology market, business development, sales growth, and oncology market expansion. Sigrid Schreiner joins as Senior Vice President of Global Market Access, adding decades of market access experience to the leadership team, including the market launch of chemotherapy Abraxane®. ImmunityBio, Inc. (NASDAQ:IBRX), a clinical-stage immunotherapy company, today announced two key executive